Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: Randomised, double blind, parallel group study

British Medical Journal

Volumn 326, Issue 7403, 2003, Pages 1367-1370

  Berth Jones, John ^a   Damstra, Robert J ^b   Golsch, Stefan ^c   Livden, John K ^d   Van Hooteghem, Oliver ^e   Allegra, Fulvio ^f   Parker, Christine A ^g  

^a WALSGRAVE HOSPITAL   (United Kingdom)

^b NIJ SMELLINGHE HOSPITAL   (Netherlands)

^c Hudpoliklinikken ^*  (Germany)

^d Hudpoliklinikken   (Norway)

^e Clinique & Maternite Sainte Elisabeth Namer   (Belgium)

^f UNIVERSITY OF PARMA   (Italy)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BATH OIL; EMOLLIENT AGENT; FLUTICASONE PROPIONATE; OIL; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; ATOPIC DERMATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DISEASE CONTROL; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EAR NOSE THROAT DISEASE; ECZEMA; ERYSIPELAS; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OINTMENT; OTORHINOLARYNGOLOGICAL INFECTION; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SKIN ATROPHY;

ADOLESCENT; ADULT; AGED; ANDROSTADIENES; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EMOLLIENTS; HUMANS; MIDDLE AGED; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 0037560964     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments of atopic eczema. Health Technol Assess 2000;4:1-191.
2. Thomas KS, Armstrong S, Avery A, Li Wan Po A, O'Neill C, Young S, et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ 2002;324:768-71.
3. Hanifin JM, Tofte SJ. Update on therapy of atopic dermatitis. JACI 1999;104:S123-5.
4. Van der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF. Coenraads PJ. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Br J Dermatol 1999;140:1114-21.
5. Spencer CM, Wiseman LR. Topical fluticasone propionate. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Biodrugs 1997;4:318-34.
6. Dykes P, Marks R, Hill S, Mills C, Eastwood R. The kinetics of skin thinning induced by topical fluticasone propionate 0.05% cream in volunteer subjects. Clin Exp Dermatol 1996;21:185-189.
7. Westerhof W, Nieuweboer-Krobotova L, Mulder P, Glazenburg E. Left-right comparison study of the combination of fluticasone propionate and UV-A vs either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol 1999;135:1061-6.
8. Friedlander SF Hebert A. Allen DB. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 2002;46:387-93.
9. Tschen E, Bucko A. Assessment of HPA-axis suppression with fluticasone cream 0.05% in patients with extensive psoriasis or eczema. Clin Drug Invest 1998;16:111-6.
10. Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, et al. The UK Working Party's Diagnostic criteria for atopic dermatitis I: Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994:131:383-96.
11. Wolkerstorfer A, De Waard-Van der Spek FB, Glazenburg EJ, Mulder PCH, Oranje AP. Scoring the scverity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre-screening tool for studies. Acta Derm Venereol 1999;79:356-9.
12. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. London: BMA. RPS, 2000:508-20. (No 40.)
13. Kaidbey KH, Kligman AM. Assay of topical corticosteroids by suppression of experimental inflammation in humans. J Invest Dermatol 1974:63:292-7.
14. Fleischer AB. Atopic dermatitis. Perspectives on a manageable disease. Postgrad Med 1999;106:49-53.